However, a genetic confirmation of the PML/RARA fusion transcript is mandatory and is carried out by RT-PCR or RT-QLAMP, and it should be performed by turnaround times of 24–48 h in order to warrant a rapid treatment start, which is associated with a reduction in the rate of bleeding complications, the major cause of early death in APL (15, 17–19). The gene discussed is RARA; the disease is acute promyelocytic leukemia.